BACKGROUND
Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). We compared iza-bren with plati...
Shao-Dong Hong, Ting Zhou, Xue Hou et al.· The Lancet· 0 citations
Background Iparomlimab and tuvonralimab (QL1706) is a MabPair product consisting of PD-1 and CTLA-4 monoclonal antibodies. This single-arm, multicenter, phase 2 study assessed the safety and efficacy of first-line QL1706 plus etoposide and carboplatin (EC) for extensive-stage small cell lung cancer (ES-SCLC). Methods P...
Yun Fan, Run-Xiang Yang, Xu-Hong Min et al.· Frontiers in Immunology· 0 citations
Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.
Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al.· Journal of Thoracic Oncology· 0 citations
PURPOSE
Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti-PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combin...
Dan-Yun Ruan, Feng-hua Wang, Yu-Juan Zhou et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.